|
1
|
Agathocleous M and Harris WA: Metabolism
in physiological cell proliferation and differentiation. Trends
Cell Biol. 23:484–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hofmockel G: Molecular genetic principles
of tumor development and progression. Urologe A. 39:212–213.
2000.(In German).
|
|
3
|
Shibata D and Aaltonen LA: Genetic
predisposition and somatic diversification in tumor development and
progression. Adv Cancer Res. 80:83–114. 2001. View Article : Google Scholar
|
|
4
|
Lee EY and Muller WJ: Oncogenes and tumor
suppressor genes. Cold Spring Harb Perspect Biol.
2:a0032362010.PubMed/NCBI
|
|
5
|
Okuyama T, Maehara Y, Kabashima A,
Takahashi I, Kakeji Y and Sugimachi K: Combined evaluation of
expressions of p53 and p21 proteins as prognostic factors for
patients with gastric carcinoma. Oncology. 63:353–361. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vadgama JV, Scuric Z, Chakrabarti R, Marzo
E, Shen D and Wu Y: Insulin-like growth factor I differentially
regulates the expression of HIRF1/hCAF1 and BTG1 genes in human
MCF-7 breast cancer cells. Int J Mol Med. 18:129–139.
2006.PubMed/NCBI
|
|
7
|
Cortes U, Moyret-Lalle C, Falette N,
Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP
and Puisieux A: BTG gene expression in the p53-dependent and
-independent cellular response to DNA damage. Mol Carcinog.
27:57–64. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Winkler GS: The mammalian
anti-proliferative BTG/Tob protein family. J Cell Physiol.
222:66–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rouault JP, Rimokh R, Tessa C, Paranhos G,
Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP:
BTG1, a member of a new family of antiproliferative genes. EMBO J.
11:1663–1670. 1992.PubMed/NCBI
|
|
10
|
Rouault JP, Falette N, Guéhenneux F,
Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P,
Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C
and Puisieux A: Identification of BTG2, an antiproliferative
p53-dependent component of the DNA damage cellular response
pathway. Nat Genet. 14:482–486. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsuda S, Rouault J, Magaud J and Berthet
C: In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS
Lett. 497:67–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bozec A, Peyrade F and Milano G: Molecular
targeted therapies in the management of head and neck squamous cell
carcinoma: recent developments and perspectives. Anticancer Agents
Med Chem. 13:389–402. 2013.PubMed/NCBI
|
|
13
|
Suzuki K, Nakamura K, Kato K, Hamada H and
Tsukamoto T: Exploration of target molecules for prostate cancer
gene therapy. Prostate. 67:1163–1173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Turashvili G, Bouchal J, Ehrmann J,
Fridman E, Skarda J and Kolar Z: Novel immunohistochemical markers
for the differentiation of lobular and ductal invasive breast
carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
151:59–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ranganathan V and De PK: Western blot of
proteins from Coomassie-stained polyacrylamide gels. Anal Biochem.
234:102–104. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Meerloo J, Kaspers GJ and Cloos J:
Cell sensitivity assays: the MTT assay. Methods Mol Biol.
731:237–245. 2011.PubMed/NCBI
|
|
17
|
Rasola A and Geuna M: A flow cytometry
assay simultaneously detects independent apoptotic parameters.
Cytometry. 45:151–157. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kramer N, Walzl A, Unger C, Rosner M,
Krupitza G, Hengstschläger M and Dolznig H: In vitro cell
migration and invasion assays. Mutat Res. 752:10–24. 2013.
View Article : Google Scholar
|
|
19
|
Richards RJ: Responsibility for
statistical analyses. Endocr Pract. 9:3292003.PubMed/NCBI
|
|
20
|
Zhu R, Zou ST, Wan JM, Li W, Li XL and Zhu
W: BTG1 inhibits breast cancer cell growth through induction of
cell cycle arrest and apoptosis. Oncol Rep. 30:2137–2144.
2013.PubMed/NCBI
|
|
21
|
Manjili MH, Najarian K and Wang XY:
Signatures of tumor-immune interactions as biomarkers for breast
cancer prognosis. Future Oncol. 8:703–711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martinez-Outschoorn UE, Pavlides S, Sotgia
F and Lisanti MP: Mitochondrial biogenesis drives tumor cell
proliferation. Am J Pathol. 178:1949–1952. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koff A, Cross F, Fisher A, Schumacher J,
Leguellec K, Philippe M and Roberts JM: Human cyclin E, a new
cyclin that interacts with two members of the CDC2 gene family.
Cell. 66:1217–1228. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tirone F: The gene PC3(TIS21/BTG2),
prototype member of the PC3/BTG/TOB family: regulator in control of
cell growth, differentiation, and DNA repair? J Cell Physiol.
187:155–165. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicholson DW and Thornberry NA: Apoptosis.
Life and death decisions. Science. 299:214–215. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corjay MH, Kearney MA, Munzer DA, Diamond
SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly
expressed in apoptotic cells in macrophage-rich areas of advanced
lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab
Invest. 78:847–858. 1998.
|
|
27
|
Lee H, Cha S, Lee MS, Cho GJ, Choi WS and
Suk K: Role of antiproliferative B cell translocation gene-1 as an
apoptotic sensitizer in activation-induced cell death of brain
microglia. J Immunol. 171:5802–5811. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nahta R, Yuan LX, Fiterman DJ, Zhang L,
Symmans WF, Ueno NT and Esteva FJ: B cell translocation gene 1
contributes to antisense Bcl-2-mediated apoptosis in breast cancer
cells. Mol Cancer Ther. 5:1593–1601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wiseman BS and Werb Z: Stromal effects on
mammary gland development and breast cancer. Science.
296:1046–1049. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alok C and Bharat B: Nuclear factor-kappa
Band cancer: its role in prevention and therapy. Biochem Phamacol.
64:883–888. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Virós D, Camacho M, Zarraonandia I, García
J, Quer M, Vila L and León X: Prognostic role of MMP-9 expression
in head and neck carcinoma patients treated with radiotherapy
orchemoradiotherapy. Oral Oncol. 49:322–325. 2013.PubMed/NCBI
|
